Short Bowel Syndrome KOL Perception Study: SBS Treatment Trends, Enteral Autonomy, and the Future of SBS-IF Innovation
A Short Bowel Syndrome KOL Perception Study exploring SBS Treatment Trends, SBS-IF Market Intelligence, enteral autonomy in SBS, GLP-2 therapies in SBS, SBS unmet needs, and future treatment innovation across the United States and Europe.
Introduction
Short Bowel Syndrome Treatment Landscape
The Short Bowel Syndrome (SBS) and Short Bowel Syndrome-Associated Intestinal Failure (SBS-IF) treatment landscape is undergoing a significant transformation. Historically, treatment strategies focused primarily on reducing parenteral nutrition dependence, but clinical priorities are increasingly shifting toward achieving long-term enteral autonomy in SBS patients.
To better understand evolving clinical perspectives, a Short Bowel Syndrome KOL Perception Study was conducted among 30 leading experts across the United States and Europe. This SBS KOL Survey assessed current treatment priorities, emerging innovations, unmet needs, and expectations for the future of SBS management.
The findings provide valuable SBS expert insights into the evolving Short Bowel Syndrome treatment landscape, highlighting the growing importance of enteral autonomy, the impact of GLP-2 therapies, and future opportunities for SBS treatment innovation.
Study Objective
To assess KOL perceptions regarding current SBS Treatment Trends, key SBS clinical outcomes, unmet needs, and the future evolution of the SBS-IF treatment landscape.
This study provides practical Short Bowel Syndrome Market Research and SBS-IF Clinical Trends for pharmaceutical companies, medical affairs teams, and rare disease stakeholders.
Respondent Profile
This KOL perception study on short bowel syndrome treatment trends delivers directional intelligence on enteral autonomy rates, parenteral nutrition dependence, GLP-2 therapies, and future treatment innovation opportunities.
Detailed Findings
SBS Treatment Trends and KOL Insights
GLP-2 therapies were viewed as the most impactful recent SBS treatment trend.
- Increased GLP-2 use: Total 40%; US 47%; EU 33%.
- Multidisciplinary care: Total 23%; US 20%; EU 27%.
- GLP-2 therapies are reshaping SBS patient management.
Enteral autonomy emerged as the primary treatment goal in SBS.
- Enteral autonomy: Total 47%; US 53%; EU 40%.
- Reduction in PN volume/days: Total 27%; US 27%; EU 27%.
- Experts increasingly view autonomy as the gold-standard outcome.
Clinical success endpoints are shifting toward patient independence.
- Enteral autonomy: Total 43%; US 47%; EU 40%.
- PN volume reduction: Total 30%; US 27%; EU 33%.
- Autonomy is becoming the preferred SBS clinical success endpoint.
Experts expressed strong confidence in current GLP-2 therapies.
- High impact rating: Total 80%; US 87%; EU 73%.
- GLP-2 therapies improve intestinal adaptation and reduce PN dependence.
- KOLs still seek therapies that drive higher complete autonomy rates.
Higher enteral autonomy rates remain the leading unmet need.
- Higher enteral autonomy rates: Total 33%; US 40%; EU 27%.
- Durable long-term efficacy: Total 27%; US 20%; EU 33%.
- EU experts placed greater emphasis on durability.
Greater autonomy rates are expected to drive future SBS therapy adoption.
- Greater autonomy rates: Total 37%; US 40%; EU 33%.
- Longer durability: Total 23%; US 20%; EU 27%.
- Treatment differentiation will depend on durable patient independence.
Q7
Future of SBS Treatment Innovation
Experts believe the next era of SBS and SBS-IF treatment will be shaped by next-generation intestinal adaptation therapies and expanded use of GLP-2 therapies.
Future SBS Landscape
Next-generation intestinal adaptation therapies were selected by 40% of KOLs overall, including 33% of US KOLs and 47% of EU KOLs. Expanded GLP-2 utilization was selected by 27% overall, including 33% of US KOLs and 20% of EU KOLs.
Innovation Insight
While current GLP-2 therapies have improved SBS patient management, KOLs expect future breakthroughs to come from therapies capable of delivering more durable and meaningful improvements in intestinal function.
Market Intelligence Insight
These findings provide valuable insight into future treatment trends in SBS and SBS-IF and highlight the broader direction of SBS treatment innovation, rare disease commercialization, and SBS-IF market intelligence.
Key Executive Insights
Key Findings from the Short Bowel Syndrome KOL Perception Study
| Key Finding | Result |
|---|---|
| Most Impactful Recent Trend | Increased use of GLP-2 therapies was selected by 40% of KOLs. |
| Primary Treatment Goal | Achieving enteral autonomy was identified by 47% of KOLs as the leading treatment goal. |
| Preferred Clinical Success Endpoint | Enteral autonomy was selected by 43% of KOLs as the preferred SBS clinical success endpoint. |
| Perceived Impact of GLP-2 Therapies | 80% of KOLs rated GLP-2 therapies as highly impactful in SBS management. |
| Biggest Unmet Need | Higher rates of enteral autonomy were identified as the leading unmet need by 33% of KOLs. |
| Most Important Future Therapy Attribute | Greater autonomy rates were selected by 37% of KOLs as the most important future therapy attribute. |
| Most Impactful Future Trend | Next-generation intestinal adaptation therapies were selected by 40% of KOLs. |
The study demonstrates that clinicians increasingly view enteral autonomy as the gold-standard outcome in SBS care. While GLP-2 therapies in SBS have significantly improved patient management, substantial opportunities remain to improve long-term outcomes and reduce reliance on parenteral nutrition.
Industry Insight
Implications for Pharma, Medical Affairs, and Market Intelligence Teams
Beyond clinical care, these findings have important implications for organizations involved in Short Bowel Syndrome market research, SBS-IF market intelligence, and rare disease commercialization.
Medical affairs and commercial teams increasingly rely on Healthcare Expert Mapping, Healthcare Professional Intelligence, and Medical Affairs Intelligence solutions to identify key stakeholders and understand changing treatment priorities.
Advanced KOL Intelligence Platforms, KOL Analytics Platforms, Scientific Collaboration Analytics, and Pharma Network Analytics tools are helping organizations strengthen evidence-generation strategies and improve engagement with influential experts.
For companies operating in rare diseases, KOL Identification in Rare Diseases has become a critical capability for understanding treatment adoption patterns, expert sentiment, and emerging opportunities within the rare disease market intelligence ecosystem.
Conclusion
Overall Study Conclusion
This Short Bowel Syndrome KOL Perception Study demonstrates that the modern Short Bowel Syndrome treatment landscape is evolving beyond incremental reductions in parenteral nutrition dependence toward achieving sustained enteral autonomy.
While GLP-2 therapies in SBS are viewed as the most impactful recent advancement, experts continue to identify significant opportunities to improve long-term outcomes and increase autonomy rates. Looking ahead, next-generation intestinal adaptation therapies are expected to define the next era of SBS treatment innovation.
For pharmaceutical companies, medical affairs teams, and rare disease stakeholders, these findings provide valuable strategic direction for future research, clinical development, and commercialization efforts.
FAQs
Frequently Asked Questions
What is Short Bowel Syndrome (SBS)?
Short Bowel Syndrome is a rare gastrointestinal condition characterized by inadequate intestinal length or function, resulting in impaired nutrient and fluid absorption.
What is SBS-IF?
SBS-IF refers to Short Bowel Syndrome-Associated Intestinal Failure, where patients require parenteral nutrition to maintain adequate nutritional status.
Why is enteral autonomy important in SBS?
Enteral autonomy eliminates the need for parenteral nutrition, improving quality of life and reducing healthcare burden.
What do SBS expert insights reveal about future treatment priorities?
Experts believe achieving higher enteral autonomy rates and durable long-term efficacy should be the primary goals of future therapies.
What is the impact of GLP-2 therapies on SBS management?
GLP-2 therapies are widely viewed as the most impactful recent advancement due to their ability to improve intestinal adaptation and reduce parenteral nutrition dependence.
What are the biggest unmet needs in SBS treatment?
Higher enteral autonomy rates and durable long-term efficacy remain the most important unmet needs identified by SBS KOLs.
What will shape the future of SBS treatment?
Next-generation intestinal adaptation therapies are expected to become the primary driver of SBS treatment innovation over the next five years.
Why is SBS-IF market intelligence important?
SBS-IF market intelligence helps pharma, medical affairs, and rare disease teams understand treatment adoption, KOL sentiment, unmet needs, and future commercialization opportunities.
